強度変調放射線治療市場 : 2028年までの世界予測

Report Overview

The global intensity-modulated radiotherapy market is projected to reach USD 2.8 billion by 2028 from USD 2.2 billion in 2023, growing at a CAGR of 5.2% during the forecast period. The projected surge in market growth for the Intensity-modulated radiotherapy market (IMRT) is underpinned by a confluence of compelling advantages. Notably, IMRT ‘capacity to achieve exceptional precision in tumor targeting, coupled with its ability to mitigate collateral damage to healthy tissues, stands as a pivotal driver. Furthermore, the escalating global incidence of cancer amplifies the demand for advanced treatment modalities, with IMRT positioned as a forefront solution. This convergence of factors is poised to usher in a phase of robust expansion within the market, consequently shaping the landscape of IMRT adoption in the forthcoming forecasting years.

“The Brain cancer application segment to register highest CAGR over the forecast period of 2023-2027”
Based on the application, the Intensity-modulated radiotherapy market is segmented into prostate cancer, lung cancer, head & neck cancer, breast cancer, gastrointestinal cancer, gynecological cancer, and other applications. The Breast cancer segment is witnessed the highest growth rate In 2022. The increase in breast cancer can be seen due to aging factors, genetic factors like – inherited genetic mutations, such as BRCA1 and BRCA2, contribute to a small percentage of breast cancer cases, the use of hormone replacement therapy can be a few of the potential factors increasing the rate of breast cancers. The incidence of breast cancer may appear to be increasing, but breast cancer mortality rates have been declining due to earlier detection and advances in treatment. IMRT allows physicians and patients to eradicate the cells efficiently by using proper radiation intensity .

“Hospitals’ segment to register for the largest market share of the Intensity-modulated radiotherapy market 2022-2027”
The major end users in the Intensity-modulated radiotherapy market are hospitals. The hospitals end-user segment is estimated to hold a significant market share of the Intensity-modulated radiotherapy market during the forecast period. Hospitals, characterized by their capacity to provide a comprehensive array of medical services within a singular facility, confer a distinctive convenience to patients undergoing the Intensity-modulated radiotherapy market (IMRT). This convenience stems from the consolidation of diverse medical needs under one roof, thereby mitigating the necessity for patients to seek multiple appointments at disparate venues. This strategic amalgamation of services not only streamlines patient care but also augments the attractiveness of IMRT as a preferred treatment option. As a result, this seamless alignment of convenience and comprehensive care significantly contributes to the advancement and prominence of the Intensity-modulated radiotherapy market within hospital settings.
Technological Advances: Hospitals frequently maintain cutting-edge infrastructure and technological capabilities essential for the successful integration of the Intensity-modulated radiotherapy market (IMRT), thus assuring the ready availability of requisite resources. This pivotal attribute distinctly contributes to the advancement and fortification of the image-guided radiation therapy market.

“Asia Pacific to register significant growth rate in the market during the forecast period.”
For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for image-guided radiation therapy. There are several drivers that contributed to this growth:
The maturing demographic profile observed in APAC countries accentuates the imperative for efficacious cancer treatment modalities characterized by minimized treatment-related adverse effects. This resonance with the precision-driven attributes of the Intensity-modulated radiotherapy market (IMRT) substantiates its pivotal role in enhancing the market landscape.
The incorporation of multilingual patient care offerings within APAC hospitals, combined with the accessibility to advanced treatments like the Intensity-modulated radiotherapy market (IMRT), confers a unique allure to the region, particularly among a diverse patient spectrum. This fusion of linguistic inclusiveness and state-of-the-art medical interventions significantly enhances the region’s desirability as a favored healthcare destination, thereby fortifying its competitive position within the healthcare market landscape and concomitantly propelling the prominence of IMRT.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
• By Designation: C-level–27%, Director-level–18%, and Others–55%
• By Region: North America–50%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%

Prominent players in this market are Varian Medical Systems, Inc., Elekta (Sweden), and Accuray Incorporated (US), Hitachi (Japan) among others.

Research Coverage

• The report studies the Intensity-modulated radiotherapy market based on radiation type, application, end user, and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro markets with respect to their growth trends, prospects, and contributions to the global Intensity-modulated radiotherapy market
• The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants/smaller firms in this market with investment evaluation viability within the Intensity-modulated radiotherapy market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, growth catalysts, challenges, and prospects, thereby empowering strategic decision-making with astute discernment.

The report provides insights on the following pointers:
• Analysis of key drivers (increasing prevalence of cancer patient population, Increasing government initiatives for cancer management, advancements in non-invasive treatments through radiation therapy), restraints (Dearth of skilled radiologist/oncologist, high cost of image-guided radiation therapy treatment, Complexity of imaging technology for treatments), opportunities (Expansion of key players in emerging countries, Rising healthcare expenditure across developing countries), and challenges (Availability of alternative technology) influencing the growth of the Intensity-modulated radiotherapy market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the image-guided radiation therapy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Intensity-modulated radiotherapy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Intensity-modulated radiotherapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Siemens Healthineers AG (Germany), Elekta (Sweden), and Accuray Incorporated (US), among others.

Table of Contents

1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS AND EXCLUSIONS 22
1.3 STUDY SCOPE 23
1.3.1 MARKET SCOPE 23
1.3.2 REGIONAL SCOPE 23
1.3.3 YEARS CONSIDERED 24
1.3.4 CURRENCY CONSIDERED 24
1.4 RESEARCH LIMITATIONS 24
1.5 STAKEHOLDERS 24
1.6 RECESSION IMPACT: INTENSITY-MODULATED RADIATION THERAPY MARKET 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
FIGURE 1 RESEARCH DESIGN 26
2.1.1 SECONDARY RESEARCH 27
2.1.2 PRIMARY RESEARCH 28
2.1.2.1 Primary sources 28
FIGURE 2 KEY DATA FROM SECONDARY SOURCES 29
2.1.2.2 Breakdown of primary sources 29
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 29
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 30
2.2 MARKET SIZE ESTIMATION 30
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 31
2.2.1 BOTTOM-UP APPROACH 31
2.2.1.1 Company revenue estimation 32
FIGURE 6 COMPANY REVENUE ESTIMATION: INTENSITY-MODULATED RADIATION THERAPY MARKET 32
2.2.1.2 Customer-based market estimation 32
FIGURE 7 BOTTOM-UP APPROACH: INTENSITY-MODULATED RADIATION THERAPY MARKET 33
2.2.2 TOP-DOWN APPROACH 33
2.2.3 PRIMARY INTERVIEWS 33
FIGURE 8 TOP-DOWN APPROACH: INTENSITY-MODULATED RADIATION THERAPY MARKET 34
2.3 MARKET ESTIMATION AND DATA TRIANGULATION 35
FIGURE 9 DATA TRIANGULATION METHODOLOGY 36
2.4 MARKET SHARE ASSESSMENT 36
2.5 ASSUMPTIONS 37
2.5.1 STUDY ASSUMPTIONS 37
2.5.2 ASSUMPTIONS FOR GROWTH FORECAST MODEL 37
2.6 RISK ASSESSMENT 37
2.7 IMPACT OF RECESSION ON INTENSITY-MODULATED RADIATION THERAPY MARKET 38
3 EXECUTIVE SUMMARY 40
FIGURE 10 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2023 VS. 2028 (USD MILLION) 40
FIGURE 11 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 41
FIGURE 12 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 41
FIGURE 13 INTENSITY-MODULATED RADIATION THERAPY MARKET SHARE, BY REGION, 2022 42
4 PREMIUM INSIGHTS 43
4.1 INTENSITY-MODULATED RADIATION THERAPY MARKET OVERVIEW 43
FIGURE 14 INCREASING PREVALENCE OF CANCER AND GROWING GERIATRIC POPULATION TO DRIVE MARKET 43
4.2 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE AND COUNTRY 44
FIGURE 15 PHOTON RADIATION AND US COMMANDED LARGEST MARKET SHARE IN 2022 44
4.3 REGIONAL SNAPSHOT OF INTENSITY-MODULATED RADIATION THERAPY MARKET 45
FIGURE 16 MIDDLE EAST & AFRICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 45
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 46
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: INTENSITY-MODULATED RADIATION THERAPY MARKET 46
5.2.1 DRIVERS 47
5.2.1.1 Rising prevalence of chronic diseases among all age groups 47
FIGURE 18 NEW CANCER CASES GLOBALLY, 2020 47
5.2.1.2 Advancements in radiation therapy technologies to improve treatment and reduce side effects 47
5.2.1.3 Improved patient outcomes and potential cost savings in long run 48
5.2.1.4 Reduced infection risk and shorter recovery periods with minimal scarring 48
5.2.2 RESTRAINTS 49
5.2.2.1 Dearth of skilled radiologists/oncologists for operating automated radiotherapy equipment 49
5.2.2.2 High cost of intensity-modulated radiation therapy systems 49
5.2.3 OPPORTUNITIES 50
5.2.3.1 Rapid economic development and rising healthcare expenditure across emerging economies 50
5.2.3.2 Growing government and private investments in cancer treatment 50
5.2.3.3 Increased adoption of radiation therapy as primary treatment option for cancer 51
5.2.4 CHALLENGES 52
5.2.4.1 Increased risk of radiation exposure for both patients and healthcare staff 52
5.2.4.2 Increased competition from alternative treatment modalities 52
5.3 KEY STAKEHOLDERS AND BUYING CRITERIA 53
5.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 53
TABLE 1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INTENSITY-MODULATED RADIATION THERAPY PRODUCTS 53
5.4 PORTER’S FIVE FORCES ANALYSIS 53
TABLE 2 PORTER’S FIVE FORCES ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 53
5.4.1 THREAT OF NEW ENTRANTS 54
5.4.2 THREAT OF SUBSTITUTES 54
5.4.3 BARGAINING POWER OF SUPPLIERS 54
5.4.4 BARGAINING POWER OF BUYERS 54
5.4.5 INTENSITY OF COMPETITIVE RIVALRY 54
5.5 REGULATORY ANALYSIS 55
5.5.1 US 55
TABLE 3 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 56
5.5.2 EUROPEAN COUNTRIES 56
5.5.3 JAPAN 56
TABLE 4 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 57
5.6 REIMBURSEMENT SCENARIO ANALYSIS 57
TABLE 5 CPT CODES FOR MAJOR INTENSITY-MODULATED RADIATION THERAPY PROCEDURES 57
TABLE 6 FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022 58
5.7 ECOSYSTEM MARKET MAP 59
FIGURE 19 ECOSYSTEM MARKET MAP: INTENSITY-MODULATED RADIATION THERAPY MARKET 59
5.8 VALUE CHAIN ANALYSIS 59
5.8.1 TECHNOLOGY INNOVATION 60
5.8.2 PROCUREMENT AND PRODUCT DESIGN 60
5.8.3 MARKETING, SALES, AND DISTRIBUTION AND POST-SALES SERVICES 60
FIGURE 20 VALUE CHAIN ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 60
5.9 SUPPLY CHAIN ANALYSIS 61
5.9.1 PROMINENT COMPANIES 61
5.9.2 SMALL & MEDIUM-SIZED COMPANIES 61
5.9.3 END USERS 61
FIGURE 21 SUPPLY CHAIN ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 61
5.10 PRICING ANALYSIS 62
5.11 PATENT ANALYSIS 62
FIGURE 22 TOP 10 PATENT APPLICANTS IN INTENSITY-MODULATED RADIATION THERAPY MARKET 62
FIGURE 23 TOP 10 PATENT OWNERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET 63
5.12 TECHNOLOGY ANALYSIS 63
TABLE 7 IMPORTANT PRODUCT LAUNCHES IN INTENSITY-MODULATED RADIATION THERAPY MARKET (JANUARY 2015–JUNE 2022) 63
5.13 KEY CONFERENCES AND EVENTS IN 2023–2024 64
TABLE 8 DETAILED LIST OF KEY CONFERENCES AND EVENTS IN INTENSITY-MODULATED RADIATION THERAPY MARKET (2023–2024) 64
6 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION 65
6.1 INTRODUCTION 66
TABLE 9 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 66
6.2 PROSTATE CANCER 66
6.2.1 ADVANCEMENTS IN NONINVASIVE RADIATION THERAPY TECHNOLOGY TO DRIVE MARKET 66
TABLE 10 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 67
6.3 BREAST CANCER 67
6.3.1 LIFESTYLE CHANGES AND FOCUS ON EARLY DETECTION THROUGH SCREENING PROGRAMS TO DRIVE MARKET 67
TABLE 11 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 68
6.4 LUNG CANCER 68
6.4.1 INCREASING RESEARCH AND CLINICAL TRIAL ACTIVITY TO DRIVE MARKET 68
TABLE 12 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 69
6.5 GASTROINTESTINAL CANCER 69
6.5.1 RISING CONSUMPTION OF SALT-PRESERVED FOOD AND ALCOHOL TO DRIVE MARKET 69
TABLE 13 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR GASTROINTESTINAL CANCER, BY REGION, 2021–2028 (USD MILLION) 69
6.6 BRAIN CANCER 70
6.6.1 NEGLIGENCE IN PRE-SCREENING PROCEDURES TO LIMIT MARKET 70
TABLE 14 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR BRAIN CANCER, BY REGION, 2021–2028 (USD MILLION) 70
6.7 OTHER CANCERS 70
TABLE 15 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 71
7 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE 72
7.1 INTRODUCTION 73
TABLE 16 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 73
7.2 PHOTON RADIATION 73
7.2.1 RISING CANCER CASES GLOBALLY TO DRIVE MARKET 73
TABLE 17 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR PHOTON RADIATION, BY REGION, 2021–2028 (USD MILLION) 74
7.3 ELECTRON RADIATION 74
7.3.1 TECHNIQUE LIMITATIONS AND REDUCED TREATMENT EFFECTIVENESS TO LIMIT ADOPTION 74
TABLE 18 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR ELECTRON RADIATION, BY REGION, 2021–2028 (USD MILLION) 74
7.4 PROTON RADIATION 75
7.4.1 EASY, PRECISE DOSAGE DELIVERY TO CANCEROUS TISSUES TO DRIVE USAGE 75
TABLE 19 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR PROTON RADIATION, BY REGION, 2021–2028 (USD MILLION) 75
7.5 CARBON-ION RADIATION 76
7.5.1 NEED FOR SPECIALIZED FACILITIES AND TREATMENT ROOMS FOR HEAVY ION-BASED THERAPIES TO LIMIT MARKET 76
TABLE 20 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR CARBON-ION RADIATION, BY REGION, 2021–2028 (USD MILLION) 76
8 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER 77
8.1 INTRODUCTION 78
TABLE 21 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 78
8.2 HOSPITALS 78
8.2.1 RAPID ADOPTION OF INVASIVE TECHNOLOGIES AND INCREASED NUMBER OF CANCER PATIENTS TO DRIVE MARKET 78
TABLE 22 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 79
8.3 INDEPENDENT RADIOTHERAPY CENTERS 79
8.3.1 LOWER OVERHEAD COSTS AND SHORTER WAITING PERIOD TO DRIVE MARKET 79
TABLE 23 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2021–2028 (USD MILLION) 80
9 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY REGION 81
9.1 INTRODUCTION 82
TABLE 24 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 82
9.2 NORTH AMERICA 83
FIGURE 24 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET SNAPSHOT 83
TABLE 25 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 26 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 84
TABLE 27 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 85
TABLE 28 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 85
9.2.1 NORTH AMERICA: RECESSION IMPACT 85
9.2.2 US 86
9.2.2.1 US dominated North American intensity-modulated radiation therapy market in 2022 86
TABLE 29 US: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 86
9.2.3 CANADA 86
9.2.3.1 Increasing prevalence of cancer and high demand for timely diagnosis to drive market 86
TABLE 30 CANADA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 87
9.3 EUROPE 87
TABLE 31 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 32 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 88
TABLE 33 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 88
TABLE 34 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 89
9.3.1 EUROPE: RECESSION IMPACT 89
9.3.2 GERMANY 89
9.3.2.1 Increasing geriatric population and rising life expectancy to drive market 89
TABLE 35 GERMANY: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 90
9.3.3 FRANCE 90
9.3.3.1 Increasing government initiatives for better healthcare practices to drive market 90
TABLE 36 FRANCE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 90
9.3.4 UK 91
9.3.4.1 High burden of cancer and rising preference for noninvasive cancer management to drive market 91
TABLE 37 UK: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 91
9.3.5 ITALY 91
9.3.5.1 Increasing geriatric population and rising use of noninvasive cancer treatment methods to drive market 91
TABLE 38 ITALY: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 92
9.3.6 SPAIN 92
9.3.6.1 Increasing technological developments in healthcare to drive market 92
TABLE 39 SPAIN: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 92
9.3.7 REST OF EUROPE 93
TABLE 40 REST OF EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 93
9.4 ASIA PACIFIC 93
FIGURE 25 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET SNAPSHOT 94
TABLE 41 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 42 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 95
TABLE 43 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96
TABLE 44 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 96
9.4.1 ASIA PACIFIC: RECESSION IMPACT 96
9.4.2 JAPAN 97
9.4.2.1 Increased geriatric population and presence of well-established healthcare sector to drive market 97
TABLE 45 JAPAN: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 97
9.4.3 CHINA 98
9.4.3.1 Growing prevalence of cancer and developing healthcare infrastructure to drive market 98
TABLE 46 CHINA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 98
9.4.4 INDIA 99
9.4.4.1 Increasing target patient population and rising availability of advanced surgical treatments to drive market 99
TABLE 47 INDIA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 99
9.4.5 AUSTRALIA 99
9.4.5.1 Developing healthcare sector with increasing availability of advanced surgical and imaging procedures to drive market 99
TABLE 48 AUSTRALIA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 100
9.4.6 SOUTH KOREA 100
9.4.6.1 Growing target cancer patient population and increasing awareness of early cancer diagnosis to drive market 100
TABLE 49 SOUTH KOREA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 100
9.4.7 REST OF ASIA PACIFIC 101
TABLE 50 REST OF ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 101
9.5 LATIN AMERICA 101
TABLE 51 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 52 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 102
TABLE 53 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
TABLE 54 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.5.1 LATIN AMERICA: RECESSION IMPACT 103
9.5.2 BRAZIL 104
9.5.2.1 Developing healthcare sector and increasing availability of advanced surgical treatments to drive market 104
TABLE 55 BRAZIL: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 104
9.5.3 MEXICO 104
9.5.3.1 Favorable government initiatives and low-cost manufacturing advantages to drive market 104
TABLE 56 MEXICO: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 105
9.5.4 REST OF LATIN AMERICA 105
TABLE 57 REST OF LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 105
9.6 MIDDLE EAST & AFRICA 106
9.6.1 FAVORABLE GOVERNMENT INITIATIVES AND ECONOMIC GROWTH TO DRIVE MARKET 106
TABLE 58 MIDDLE EAST & AFRICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 106
TABLE 59 MIDDLE EAST & AFRICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 107
TABLE 60 MIDDLE EAST & AFRICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 107
10 COMPETITIVE LANDSCAPE 108
10.1 OVERVIEW 108
10.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET 108
FIGURE 26 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET (2019–2023) 109
10.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS 110
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2019–2022) 110
10.4 MARKET SHARE ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY KEY PLAYER (2022) 110
FIGURE 28 INTENSITY-MODULATED RADIATION THERAPY MARKET SHARE, BY KEY PLAYER, 2022 110
10.5 COMPANY EVALUATION MATRIX FOR PLAYERS (2022) 111
10.5.1 STARS 111
10.5.2 PERVASIVE PLAYERS 111
10.5.3 EMERGING LEADERS 111
10.5.4 PARTICIPANTS 111
FIGURE 29 COMPANY EVALUATION MATRIX FOR PLAYERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET, 2022 112
10.6 COMPETITIVE BENCHMARKING 113
10.6.1 OVERALL COMPANY FOOTPRINT 113
TABLE 61 OVERALL FOOTPRINT ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 113
10.6.2 PRODUCT FOOTPRINT 113
TABLE 62 PRODUCT FOOTPRINT ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 113
10.6.3 REGIONAL FOOTPRINT 114
TABLE 63 REGIONAL FOOTPRINT ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 114
10.7 COMPETITIVE SCENARIOS AND TRENDS (2020–2023) 115
10.7.1 KEY PRODUCT LAUNCHES AND APPROVALS 115
TABLE 64 KEY PRODUCT LAUNCHES AND APPROVALS 115
10.7.2 KEY DEALS 116
TABLE 65 KEY DEALS 116
10.7.3 OTHER KEY DEVELOPMENTS 117
TABLE 66 OTHER KEY DEVELOPMENTS 117
11 COMPANY PROFILES 118
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
11.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.) 118
TABLE 67 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 118
FIGURE 30 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 119
11.2 ELEKTA 126
TABLE 68 ELEKTA: COMPANY OVERVIEW 126
FIGURE 31 ELEKTA: COMPANY SNAPSHOT (2022) 127
11.3 ACCURAY INCORPORATED 132
TABLE 69 ACCURAY INCORPORATED: COMPANY OVERVIEW 132
FIGURE 32 ACCURAY INCORPORATED: COMPANY SNAPSHOT (2022) 133
11.4 IBA WORLDWIDE 137
TABLE 70 IBA WORLDWIDE: COMPANY OVERVIEW 137
FIGURE 33 IBA WORLDWIDE: COMPANY SNAPSHOT (2022) 138
11.5 HITACHI, LTD. 141
TABLE 71 HITACHI, LTD.: COMPANY OVERVIEW 141
FIGURE 34 HITACHI, LTD.: COMPANY SNAPSHOT (2021) 142
11.6 MEVION MEDICAL SYSTEMS 144
TABLE 72 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 144
11.7 KONINKLIJKE PHILIPS N.V. 147
TABLE 73 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 147
FIGURE 35 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 148
11.8 RAYSEARCH LABORATORIES 150
TABLE 74 RAYSEARCH LABORATORIES: COMPANY OVERVIEW 150
FIGURE 36 RAYSEARCH LABORATORIES: COMPANY SNAPSHOT (2022) 151
11.9 BRAINLAB AG 154
TABLE 75 BRAINLAB AG: COMPANY OVERVIEW 154
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
12 APPENDIX 155
12.1 DISCUSSION GUIDE 155
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 160
12.3 CUSTOMIZATION OPTIONS 162
12.4 RELATED REPORTS 162
12.5 AUTHOR DETAILS 163